Drugmaker Merck’s Q4 profit, sales fall due to generic competition, unfavourable exchange rates

WHITEHOUSE STATION, N.J. – Merck & Co.’s is reporting a 14 per cent decline in fourth-quarter as generic competition cut into the sale of one-time blockbuster medicines, as well as unfavourable currency exchange rates that reduced overseas revenue.

The world’s third-biggest drugmaker reported net income of $781 million, or 26 cents per share on Wednesday, down from $908 million, or 30 cents per share, a year earlier.

The maker of Type 2 diabetes pill Januvia says that excluding one-time items, net income was $2.6 billion, or 88 cents per share. That’s a penny shy of Wall Street expectations, according to a poll by FactSet.

Revenue totalled $11.32 billion, down 4 per cent. Analysts expected $11.36 billion.

Merck, based in Whitehouse Station, N.J., forecast 2014 profit of $2.25 to $2.47 per share.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.